Skip to main content
recep.adiyaman
Vision About Experience Education Skills Publications Tools Newsletter Updates Podcasts Blog Contact CV Subscribe
All Issues
Older Newer
Daily Signal May 04, 2026 · 9 min read

Issue #100: Exploring quantum frontiers in protein structure prediction: techniques, challenges, and opportunities.

Protein Design Digest #100: Exploring quantum frontiers in protein structure prediction: techniques,…

Share X LinkedIn
Protein Design Daily

Building something in Protein Design?

I love collaborating on new challenges. Let's build together.

LinkedIn Email

Subscribe to Protein Design Digest

Daily curated signals from arXiv, PubMed, and BioRxiv.

Signal of the Day

Exploring quantum frontiers in protein structure prediction: techniques, challenges, and opportunities.

Protein folding is governed by the principle of free energy minimization, where a protein’s native tertiary structure corresponds to the global minimum on an energy landscape shaped by quantum mechanical interactions such as hydrogen bonding, van der Waals forces, and electron delocalization. Despite significant advances in template-based modeling (TBM), ab-initio simulations, and deep learning approaches, classical methods continue to face challenges due to the exponential complexity of the conformational search space and the approximations involved in modeling molecular interactions. Although AlphaFold, a deep learning-based protein modeling tool, has achieved a remarkable score of 92.4 in the critical assessment of protein structure prediction (CASP), classical protein structure prediction (PSP) remains hindered by the computational limitations of conventional binary architecture in representing the physical constraints of biomolecular systems. By representing the combinatorial explosion of possible conformations as a more tractable optimization problem, quantum computing offers a fundamentally new paradigm for protein three-dimensional (3D) structure prediction. In this review, we explore how quantum computing (QC) techniques including quantum annealing, quantum optimization algorithms, and hybrid quantum-classical approaches can leverage quantum properties such as superposition, entanglement, and tunneling to more efficiently navigate the complex energy landscapes associated with protein folding. While current challenges, including limited qubit fidelity, error correction, and scalability, remain, the integration of quantum algorithms with classical strategies holds significant promise for advancing structural biology, with profound implications for drug discovery and the understanding of complex biomolecular systems.

Why this matters: Critical for improving fold accuracy and reducing structural uncertainty in de novo design.

Also Worth Reading

Do Larger Models Really Win in Drug Discovery? A Benchmark Assessment of Model Scaling in AI-Driven Molecular Property and Activity Prediction

The rapid growth of molecular foundation models and general-purpose large language models has encouraged a scale-centric view of artificial intelligence in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models and task-specific graph neural networks (GNNs). We test this assumption on 22 molecular property and activity endpoints, including public ADMET and Tox21 benchmarks and two internal anti-infective activity datasets. Across 167,056 held-out task–molecule evaluations under structure-similarity-separated five-fold cross-validation (37,756 ADMET, 77,946 Tox21, 49,266 anti-TB and 2,088 antimalaria), classical machine-learning (ML) models such as RF(ECFP4) and ExtraTrees(RDKit descriptors) win ten primary-metric tasks, GNNs such as GIN and Ligandformer win nine, and pretrained molecular sequence models such as MoLFormer and ChemBERTa2 win three. Rule-based SAR reasoning baselines, represented by GPT5.5-SAR and Opus4.7-SAR, do not win under the prespecified primary metrics, although train-fold-derived SAR knowledge provides measurable but uneven gains for SAR reasoning and interpretation. These results indicate that compact, specialized models remain highly effective for molecular property and activity prediction. The performance differences among classical ML, GNN and pretrained sequence models are often modest and endpoint-dependent, whereas larger or more general models do not provide a universal predictive advantage. Large models may still add value for zero-shot reasoning, SAR interpretation and hypothesis generation, but the results suggest that predictive performance depends on the alignment among molecular representation, inductive bias, data regime, endpoint biology and validation protocol.

Identification of paucinervin D as a natural sphingosine-1-phosphate receptor 1 agonist: Insights from pharmacophore modeling, docking, molecular dynamics simulations, and density functional theory.

Sphingosine-1-phosphate receptor 1 (S1PR1), a member of the G protein-coupled receptor (GPCR) family, is a crucial therapeutic target for various diseases. Activation of S1PR1 has been recognized as an effective therapeutic strategy for multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. Natural products (NPs) serve as a rich source of bioactive compounds for drug discovery. Here, we aimed to discover novel S1PR1 agonists from NPs via multi-level virtual screening (VS). Using a validated HipHop pharmacophore model, we screened a database containing 54,642 NPs, followed by molecular docking. Based on binding mode analysis, four candidate S1PR1 agonists (NPC323626, NPC264112, NPC469907, and NPC22192) were selected. Subsequent molecular dynamics (MD) simulations and binding free energy calculations confirmed the stability of the receptor-ligand complexes and their binding affinities. Among the four candidates, NPC469907 exhibited the strongest binding affinity for S1PR1, with a value of -58.08 ± 0.13 kJ/mol. Furthermore, hydrogen bonds formed between NPC469907 and Glu121 of S1PR1 were found to be essential for receptor activation. Quantum mechanical calculations further revealed that the phenyl-ring-attached hydrogen site in NPC469907 could be modified without compromising its ability to activate S1PR1. The analysis of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) indicated that NPC469907 possessed favorable pharmacokinetic properties and low toxicity. In conclusion, our study identified NPC469907 as a promising natural S1PR1 agonist and established an effective VS strategy for the discovery of novel S1PR1 agonists.

Simulated construction of tilmicosin nucleic acid aptamers based on molecular docking and molecular dynamics techniques.

Traditional aptamer screening methods often prove ineffective for small molecule targets, primarily due to the inherent structural limitations of such compounds. Their simple architecture, limited functional groups, and restricted spatial complexity drastically reduce the probability of identifying nucleic acid sequences that bind with both high affinity and specificity. Consequently, the screening process becomes inefficient and labor-intensive, frequently failing to yield aptamers of satisfactory performance for practical applications. This represents a significant technical hurdle in expanding the use of aptamers in small-molecule detection and therapeutics. Based on this, this study innovatively proposes an aptamer design method based on single-nucleotide docking assembly, using the small molecule temicloxacin as an example. Through molecular dynamics simulations (50 ns, RMSD convergence threshold of 0.15 nm), the dynamic conformational characteristics of tilmicosin were analyzed. Subsequently, saturated docking was performed on four classes of mononucleotides, screening out 32 high-affinity mononucleotides (atomic contact distance ≤4 Å). Methods such as depth-first search algorithm (DFS) and weighted graph theory model were introduced to obtain the representative single nucleotides of eight classes of functional modules and linkage assembly, and finally 63 non-redundant candidate sequences were screened. Molecular docking results indicate that the optimal aptamer Til-14 exhibits high binding affinity with tilmicosin. with an affinity of 298.16 ± 95.588 nM measured via SYBR Green I fluorescence assay. Colloidal gold colorimetric analysis confirmed its high affinity (Kd = 279.323 ± 87.234 nM) and excellent specificity. This innovative method successfully addresses the key limitations of the traditional SELEX process in screening aptamers for small molecule targets. By enhancing the efficiency and specificity of selection, it not only facilitates the discovery of high-performance aptamers but also establishes a novel, generalizable framework for the construction of nucleic acid aptamers targeting other small molecules.

Research & AI Updates

From the Industry

Quick Reads

Evaluation of the mechanism underlying melatonin action in cholestatic liver disease treatment via network pharmacology, molecular docking, and in vivo experiments.

The aim of this study was to investigate the mechanism underlying the action of melatonin (MT) in treating cholestatic liver disease. Read more →

Synthesis, biological evaluation and molecular docking studies of N-propylsulfonyl indole-linked hydrazinecarbothioamides as selective ecto-5’-nucleotidase and NTPDase inhibitors.

Ectonucleotidases, including NTPDases and ecto-5’-nucleotidase (e-5’NT/CD73), regulate extracellular purinergic signaling by converting ATP to adenosine, a pathway critically involved in immune response, inflammation, and cancer progression. Read more →

Harnessing AI to decode protein kinases: Structural, functional, and therapeutic design perspectives.

Recent advances in Artificial Intelligence (AI) are reshaping kinase research by uncovering complex regulatory mechanisms and accelerating drug discovery. Read more →

Protein Language Models Trained on Biophysical Dynamics Inform Mutation Effects

Structural dynamics are fundamental to protein functions and mutation effects. Read more →

Integrated affinity ultrafiltration UHPLC-QE-Orbitrap-MS and molecular docking for efficient screening of aurora kinase a inhibitors from Eomecon chionantha Hance.

Aurora kinase A (AURKA) is a key therapeutic target for cancer, and natural products from medicinal plants are important sources for developing targeted inhibitors. Read more →

Molecular docking of polyphenols and screening of antioxidant and anticancer activity of Artemisia monosperma leaf extracts in human cancer cells.

This study evaluated the polyphenol content of leaf extracts from Artemisia monosperma (AM) and investigated their antioxidant properties, cytotoxic effects, and potential to induce DNA damage in human cancer cell lines. Read more →

Structure-based identification of GIRK2-PIP2 modulators: Integrative docking, MM-GBSA, ADMET, and molecular dynamics study.

G protein-gated inwardly rectifying potassium (GIRK) channels are key regulators of neuronal excitability, making them promising therapeutic targets for central nervous system disorders. Read more →

DecoyFinderNetAna: Application of Graph Convolution Neural Networks for Accurate Classification of True Small Molecule Binders from their Decoys.

Introduction The drug discovery pipeline faces significant challenges, often requiring extensive screening to differentiate between true ligands and decoys. Read more →

Pipeline Tip

Pin reference genomes by checksum to avoid version drift.

Resources & Tools

The protein structure is the language of life; design is its poetry. — Recep Adiyaman

BS HF DK